Smith & Nephew (LON:SN) Hits New 1-Year High – Here’s Why

Smith & Nephew plc (LON:SN) hit a new 52-week high on Friday . The stock traded as high as GBX 1,250.50 and last traded at GBX 1,248, with a volume of 1196793 shares trading hands. The stock had previously closed at GBX 1,240.50.

Analyst Ratings Changes

Several brokerages have recently commented on SN. Royal Bank Of Canada downgraded Smith & Nephew to a “sector perform” rating and lowered their price objective for the stock from GBX 1,700 to GBX 1,350 in a research note on Wednesday, December 17th. Berenberg Bank reaffirmed a “hold” rating and set a GBX 1,300 target price on shares of Smith & Nephew in a research report on Friday, January 23rd. Finally, Panmure Gordon reiterated a “hold” rating and set a GBX 1,200 price target on shares of Smith & Nephew in a report on Tuesday, December 9th. Two equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of GBX 1,381.33.

Smith & Nephew Price Performance

The firm has a market cap of £13.68 billion, a PE ratio of 44.93, a P/E/G ratio of 0.46 and a beta of 0.68. The company has a debt-to-equity ratio of 62.90, a current ratio of 2.57 and a quick ratio of 0.84. The business’s fifty day moving average is GBX 1,272.11 and its 200-day moving average is GBX 1,298.93.

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.